We outline a general coalescent framework for using genotype data in linkage disequilibrium-based mapping studies. Our approach unifies two main goals of gene mapping that have generally been treated separately in the past: detecting association (i.e., significance testing) and estimating the location of the causative variation. To tackle the problem, we separate the inference into two stages. First, we use Markov chain Monte Carlo to sample from the posterior distribution of coalescent genealogies of all the sampled chromosomes without regard to phenotype. Then, averaging across genealogies, we estimate the likelihood of the phenotype data under various models for mutation and penetrance at an unobserved disease locus. The essential signal that these models look for is that in the presence of disease susceptibility variants in a region, there is nonrandom clustering of the chromosomes on the tree according to phenotype. The extent of nonrandom clustering is captured by the likelihood and can be used to construct significance tests or Bayesian posterior distributions for location. A novelty of our framework is that it can naturally accommodate quantitative data. We describe applications of the method to simulated data and to data from a Mendelian locus (CFTR, responsible for cystic fibrosis) and from a proposed complex trait locus (calpain-10, implicated in type 2 diabetes).
O NE of the primary goals of modern genetics is to (1996) argued that, under certain assumptions, associaunderstand the genetic basis of complex traits.
tion mapping is far more powerful than family-based What are the genes and alleles that contribute to suscepmethods. They proposed that to unravel the basis of tibility to a particular disease, and how do they interact complex traits, the field needed to develop the technical with each other and with environmental and stochastic tools for genome-wide association studies (including a factors to produce phenotypes?
genome-wide set of SNPs and affordable genotyping The traditional gene-mapping approach of positional technology). Those tools are now becoming available, cloning starts by using linkage analysis in families to and it will soon be possible to test the efficacy of genomeidentify chromosomal regions that contain genes of inwide association studies. Moreover, association mapping terest. These chromosomal regions are typically several is already extremely widely used in candidate gene studcentimorgans in size and may contain hundreds of genes.
ies (e.g., Lohmueller et al. 2003) . Next, linkage analysis is normally followed by linkage For all these studies, whether or not they start with disequilibrium and association analysis to help narrow linkage mapping, association analysis is used to try to dethe search down to the functional gene and active varitect or localize the active variants at a fine scale. At that ants (e.g., Kerem et al. 1989; Hastbacka et al. 1992) .
point, the data in the linkage disequilibrium (LD)-mapThe positional cloning approach has been very successping phase typically consist of genotypes from a subset ful at identifying Mendelian genes, but mapping genes for of the common SNPs in a region. The investigator aims complex traits has turned out to be extremely challenging to use these data to detect unobserved variants that im- (Risch 2000) . Despite these difficulties, there have been pact the trait of interest. For complex traits, it will nora mounting number of recent successes in which posimally be the case that the active variants have a relatively tional cloning has led to the identification of at-risk modest impact on total disease risk. This small signal haplotypes or occasionally causal mutations, in humans will be further attenuated if the nearest markers are in and model organisms (e.g., Horikawa et al. 2000; Gre- only partial LD with the active site (Pritchard and tarsdottir et al. 2003; Korstanje and Paigen 2002; Przeworski 2001) . Moreover, if there are multiple risk Laere et al. 2003) .
alleles in the same gene, these will often arise on differIn view of the challenges of detecting genes of small ent haplotype backgrounds and may tend to cancel out effect using linkage methods, Risch and Merikangas each other's signals.
[There is a range of views on how serious this problem of allelic heterogeneity is likely to be for complex traits (Terwilliger and Weiss 1998; 1 Figure 1.-Schematic example of the data structure. The lines indicate the chromosomes of three affected individuals (solid) and of three healthy control individuals (dashed). The solid circles indicate unobserved variants that increase disease risk. Each column of rectangles indicates the position of a SNP in the data set. The goal is to use the SNP data to detect the presence of the disease variants and to estimate their location. Note that for a complex disease we expect to see the "at-risk" alleles at appreciable frequency in controls, and we also expect to find cases without these alleles. As a further complication, there may be multiple disease mutations, each on a different haplotype background.
For all these reasons, it is important to develop statisti-
The current statistical methods in this field tend to be designed for one goal or the other, but in this article cal methods that can extract as much information from the data as possible. Certainly, some complex trait loci we describe a full multipoint approach for treating both problems in a unified coalescent framework. Our aim can be detected using very simple analyses. However, by developing more advanced statistical approaches it is to provide rigorous inference that is more accurate and more robust than existing approaches. should be possible to retain power under a wider range of scenarios: e.g., where the signal is rather weak, where
In the first part of this article, we give a brief overview of existing methods for significance testing and fine the relevant variation is not in strong LD with any single genotyped site (Carlson et al. 2003) , or where there is mapping. Then we describe the general framework of our moderate allelic heterogeneity.
approach. The middle part outlines our current impleFurthermore, for fine mapping, it is vital to use a sensimentation, developed for case-control data. Finally, we deble model to generate the estimated location of disease scribe results of applications to real and simulated data. variants as naive approaches tend to underestimate the uncertainty in the estimates (Morris et al. 2002) . EXISTING 
METHODS
In this article, we focus on the following problem. Consider a sample of unrelated individuals, each genoSignificance testing: The simplest approach to sigtyped at a set of markers across a chromosomal region nificance testing is simply to test each marker separately of interest. We assume that the marker spacing is within for association with the phenotype (using a chi-square the typical range of LD, but that it does not exhaustively test of independence, for example). This approach is sample variation. In humans this might correspond to most effective when there is a single common disease Ϸ5-kb spacing on average (Kruglyak 1999 ; Zö llner variant and less so when there are multiple variants and von Haeseler 2000; Gabriel et al. 2002) . Each (Slager et al. 2000) . When there is a single variant, individual has been measured for a phenotype of interpower is a simple function of r 2 , the coefficient of LD est, and our ultimate goal is to identify genetic variation between the disease variant and the SNP (Pritchard that contributes to this phenotype ( Figure 1) .
and Przeworski 2001) and the penetrance of the disWith such data, there are two distinct kinds of statistiease variant. In some recent mapping studies, this simcal goals:
ple test has been quite successful (e.g., Van Eerdewegh et al. 2002; Tokuhiro et al. 2003 ).
Testing for association: Do the data provide evidence
The simplest multipoint approach to significance testthat there is genetic variation in this region that coning is to use two or more adjacent SNPs to define haplotributes to the phenotype? (Typically, we would want types and then test the haplotypes for association (Daly to see a systematic difference between the genotypes et al. 2001; Johnson et al. 2001; Rioux et al. 2001 ; Greof individuals with high and low phenotype values, tarsdottir et al. 2003) . It is argued that haplotyperespectively, or between cases and controls.) The based testing may be more efficient than SNP-based strength of evidence is typically summarized using a testing at screening for unobserved variants ( Johnson P-value. 2. Fine mapping: Assuming that there is variation in Gabriel et al. 2002) . However, there is still uncertainty about how best to implement this type of region that impacts the phenotype, then what is the most likely location of the variant(s) and what is the strategy in a systematic way and how the resulting power compares to other approaches after multiple-testing corsmallest subregion that we are confident contains the variant(s)? This type of information is conveniently rections.
Various other more complex methods have been prosummarized as a Bayesian posterior distribution. posed for detecting disease association. These include Markov model for the LD between adjacent sites. The McPeek and Strahs model assumed a star-shaped geneala data-mining algorithm (Toivonen et al. 2000) , multipoint schemes for identifying identical-by-descent reogy for the case chromosomes and applied a correction factor to account for the pairwise correlation of chromogions in inbred populations (Service et al. 1999; Abney et al. 2002) , and schemes for detecting multipoint associsomes due to shared ancestry. Subsequent variations on this theme have included ation in outbred populations (Liang et al. 2001; Tzeng et al. 2003) .
other methods based on star-shaped genealogies (Morris et al. 2000; Liu et al. 2001) and methods involving Perhaps closest in spirit to the approach taken here is the cladistic approach developed by Alan Templeton bifurcating genealogies of case chromosomes including those of Rannala and Reeve (2001), Morris et al. (2002) , and colleagues (Templeton et al. 1987 ; see also Seltman et al. 2001) . Their approach is first to construct a and Lam et al. (2000) . Two other methods have also used genealogical approaches, but seem to be practical only set of cladograms on the basis of the marker data by using methods for phylogenetic reconstruction and for very small data sets or numbers of markers (Graham and Thompson 1998; Larribe et al. 2002 et al. (2003) presented a less inference scheme presented here is based on a formal population genetic model with recombination. This model-based multipoint approach to fine mapping. They used ideas from spatial statistics, grouping haplotypes should enable a more accurate estimation of topology and branch lengths. Our approach also differs from from cases and controls into distinct clusters and assessing evidence for the location of the disease mutation those methods in that we perform a more model-based analysis of the resulting genealogy.
from the distribution of cases across the clusters. Their approach may be more computationally feasible for Fine mapping: In contrast to the available methods for significance testing, the literature on fine mapping large data sets than are fully model-based genealogical methods, but it is unclear if some precision is lost by has a heavier emphasis on model-based methods that consider the genealogical relationships among chromonot using a coalescent model. The procedure described in this article differs from somes. This probably reflects the view that a formal model is necessary to estimate uncertainty accurately existing methods in several important aspects. Our approach estimates the joint genealogy of all individuals, (Morris et al. 2002) , and that estimates of location based on simple summary measures of LD do not pronot just of cases. This should allow us to model the ancestry of the sample more accurately and to include alvide accurate assessments of uncertainty. The challenge is to develop algorithms that are computationally practilelic heterogeneity in a more realistic way. We also analyze the evidence for the presence of a disease mutation cal, yet extract as much of the signal from the data as possible. The methods should work well for the intermeafter inferring the ancestry of a locus. This enables us to apply realistic models of penetrance and to analyze diate penetrance values expected for complex traits and should be able to deal with allelic heterogeneity. quantitative traits. Furthermore, in our Markov chain algorithm we do not record the full ancestral sequences Though one might ideally wish to perform inference using the ancestral recombination graph (Nordborg at every node, which should enable better mixing and allow analysis of larger data sets. 2001), this turns out to be extremely challenging computationally (e.g., Fearnhead and Donnelly 2001; Larribe et al. 2002) . Instead, most of the existing methods make MODELS AND METHODS progress by simplifying the full model in various ways to make the problem more computationally tractable
We consider the situation where the data consist of a sample of individuals who have been genotyped at a set (as we do here).
The first full multipoint, model-based method was of markers spaced across a region of interest ( Figure 1 ). Each individual has been assessed for some phenotype, developed by McPeek and Strahs (1999) . Some elements of their model have been retained in most subsewhich can be either binary (e.g., affected with a disease or unaffected) or quantitative. Our framework can also acquent models, including ours. Most importantly, they simplified the underlying model by focusing attention commodate transmission disequilibrium test data (Spielman et al. 1993) , where the untransmitted genotypes are only on the ancestry of the chromosomes at each of a series of trial positions for the disease mutation. They treated as controls.
We are most interested in the setting where the genothen calculated the likelihood of the data at each of those positions and used the likelihoods to obtain a typed markers represent only a small fraction of the variation in the region, and our goal is to use LD and point estimate and confidence interval for the location of the disease variant. Under that model, nonancestral association to detect unobserved susceptibility variants. We allow for the possibility of allelic heterogeneity (there sequence could recombine into the data set. The likelihood of nonancestral sequence was computed using the might be multiple independent mutation events that produce susceptibility alleles), but we assume that all control allele frequencies and assuming a first-degree these mutations occur close enough together (e.g., within a few kilobases) that we can treat them as having a single location within the region.
The genealogical approach: The underlying model for our approach is derived from the coalescent (reviewed by Hudson 1990; Nordborg 2001). The coalescent refers to the conceptual idea of tracing the ancestry of a sample of chromosomes back in time. Even chromosomes from "unrelated" individuals in a population share a common ancestor at some time in the past. Moving backward in time, eventually all the lineages that are ancestral to a modern day sample "coalesce" to a single common ancestor. The timescales for this process are typically rather long-for example, the most recent common ancestor of human ␤-globin sequences is estimated to have been ‫000,008ف‬ years ago (Harding et al. 1997) .
When there is recombination, the ancestral relationships among chromosomes are more complicated. At any single position along the sequence, there is still a single tree, but the trees at nearby positions may differ. It is possible to represent the full ancestral relationships among chromosomes using a concept known as the "an- on the tree represent two independent mutation events proConsidering the coalescent process provides useful ducing susceptibility variants. These are inherited by the chroinsight into the nature of the information about associamosomes marked with hatched circles. Individuals carrying tion that is contained in the data. Figure 2 shows a hypothose chromosomes will be at increased risk of disease. This means that there will be a tendency for chromosomes from thetical example of the coalescent ancestry of a sample affected individuals to cluster together on the tree, in two of chromosomes at the position of a disease susceptibilmutation-carrying clades. The degree of clustering depends ity locus. In this example, two disease susceptibility muin part on the penetrance of the mutation.
tations are present in the sample. By definition, these will be carried at a higher rate in affected individuals than in controls. This implies that chromosomes from mation to learn as much as we can about the coalescent genealogy of the sample at different points along the affected individuals will tend to be nonrandomly clustered on the tree. Each independent disease mutation chromosome. Our statistical inference for association mapping or fine mapping will be based on this. In what gives rise to one cluster of "affected" chromosomes.
Traditional methods of association mapping work by follows, we outline our approach of using marker data to estimate the unknown coalescent ancestry of a sample testing for association between the phenotype status and alleles at linked marker loci (or with haplotypes). In and describe how this information can be used to perform inference. Unlike in previous mapping methods effect, association at a marker indicates that in the neighborhood of this marker, chromosomes from affected (e.g., Morris et al. 2002) , we aim to reconstruct the genealogy of the entire sample and not just the genealindividuals are more closely related to one another than by random. Fundamentally, the marker data are inforogy of cases. This extension allows us to extract substantially more information from the data and enables sigmative because they provide indirect information about the ancestry of unobserved disease variants. Detecting nificance testing. Performing inference: We start by developing some association at noncausative SNPs implies that case chromosomes are nonrandomly clustered on the tree.
notation. Consider a sample of n haplotypes from n/2 unrelated individuals. The phenotype of individual i is In fact, unless we have the actual disease variants in our marker set, the best information that we could possibly φ i , and ⌽ represents the vector of phenotype data for the full sample of n/2 individuals. The phenotypes might get about association is to know the full coalescent genealogy of our sample at that position. If we knew this, the marker be qualitative (e.g., affected/unaffected) or quantitative measurements. genotypes would provide no extra information; all the information about association is contained in the geneEach individual is genotyped at a series of marker loci from one or more genomic regions (or in the future posalogy. Hence, our approach is to use the marker infor-sibly from genome-wide scans). Let G denote the multition about the location of the disease mutation. Thus, we ignore the possible impact of selection and overdimensional vector of haplotype data-i.e., the genotypes for n haplotypes at L loci (possibly with missing ascertainment of affected individuals in changing the distribution of branch times at the disease locus. Our data). Let X be the set of possible locations of the QTL or disease susceptibility gene and let x ʦ X represent expectation is that the data will be strong enough to overcome minor misspecification of the model in this its (unknown) position. Our approach is to scan sequentially across the regions containing genotype data, conrespect (this was the experience of Morris et al. 2002 , in a similar situation). The second approximation is a sidering many possible positions for x. A natural measure of support for the presence of a disease mutation good assumption if the active disease mutation is not actually in our marker set and if mutations at different at position x is given by the likelihood ratio (LR), positions occur independently. We can then write
where L A and L 0 represent likelihoods under the alternaand since Pr(G |T x )Pr(T x ) ϭ Pr(T x |G)Pr(G) we obtain tive model (disease mutation at x) and null hypothesis (no disease mutation in the region), respectively. P alt
and P 0 are the vectors of penetrance parameters under the alternative and null hypotheses, respectively, that
(5) maximize the likelihoods. Large values of the likelihood ratio indicate that the null hypothesis should be reExpression (5) consists of two parts. Pr(⌽|x, T x ) is the jected. Specific models to calculate these likelihoods probability of the phenotype data given the tree at x. are described below (see Equations 7 and 8).
To compute this, we specify a disease model and then We also want to estimate the location of disease mutaintegrate over the possible branch locations of disease tions. For this purpose it is convenient to adopt a Bayesmutations in the tree (see below for details). Pr(T x |G) ian framework, as this makes it more straightforward refers to the posterior density of trees given the marker to account for the various sources of uncertainty in a data and a population genetic model to be specified; coherent way (Morris et al. 2000 (Morris et al. , 2002 Liu et al. 2001) .
the next section outlines our approach to drawing The posterior probability that a disease mutation is at Monte Carlo samples from this density. x is then In summary, our approach is to scan sequentially across the region(s) of interest, considering a dense set
posterior distribution of trees. For Bayesian inference of location, we apply Equation 2 to estimate the posterior where Pr(x) gives the prior probability that the disease density Pr(x|⌽, G) at x by computing locus is at x. Pr(x) will normally be set uniform across the genotyped regions, but this prior can easily be modified to take advantage of prior genomic information if
, desired (see discussion in Rannala and Reeve 2001; Morris et al. 2002) .
(6) To evaluate expressions (1) and (2), we need to comwhere {y 1 , . . . , y Y } denote a series of Y trial values of x pute Pr(⌽, G |x). To do so, we introduce the notation spaced across the region of interest. We will occasionally T x , to represent the (unknown) coalescent genealogy refer to the numerator of Equation 6, divided by Pr(x), of the sample at x. T x records both the topology of the as the "average posterior likelihood" at x. For signifiancestral relationships among the sampled chromocance testing at x, we maximize somes and the times at each internal node. Then
with respect to P alt and P 0 . See below for details about where the integral is evaluated over all possible trees. We now make the following approximations: (i) Pr(T x |x) Ϸ how these probabilities are computed.
Sampling from the genealogy, T x : To perform these Pr(T x ) and (ii) Pr(G |⌽, x, T x ) Ϸ Pr(G |T x ). The first approximation implies that in the absence of the phenocalculations, it is necessary to sample from the posterior density, T x |G (loosely speaking, we wish to draw from type data, the tree topology itself contains no informa- the set of coalescent genealogies that are consistent with sample. It is likely that the region around the focal point shared by the three chromosomes is smaller. In our the genotype data). We adopt a fairly standard population genetic model, namely the neutral coalescent with recomrepresentation of the genealogy, we store the topology at the focal point, along with the extent of sequence at bination (i.e., the ARG; Nordborg 2001). Our current implementation assumes constant population size. each node that is ancestral to at least one of the sampled chromosomes without recombination ( Figure 3 ). A number of recent studies have aimed to perform full-likelihood or Bayesian inference under the ARG An example of this is provided in Figure 4 . Each tip of the tree records the full sequence (across the entire (Griffiths and Marjoram 1996; Kuhner et al. 2000; Nielsen 2000 ; Fearnhead and Donnelly 2001; Larregion) of one observed haplotype. Then, moving up the tree, as the result of a recombination event a part ribe et reviewed by Stephens 2001) . The experience of these earlier studies indicates that this is a of the sequence may split off and evolve on a different branch of the ARG. When this happens, the amount technically challenging problem, and that existing methods tend to perform well only for quite small data of sequence that is coevolving with the focal point is reduced. The length of the sequence fragment that sets (e.g., Wall 2000; Fearnhead and Donnelly 2001). Therefore, we have decided to perform inference under coevolves with the focal point can increase during a coalescent event, as the sequence in the resulting node a simpler, local approximation to the ARG, reasoning that this might allow accurate inference for much larger is the union of the two coalescing sequences. In other words, the amount of sequence surrounding the focal data sets. Our implementation applies Markov chain Monte Carlo (MCMC) techniques (see appendix a).
point shrinks when a recombination event occurs and may increase at a coalescent event. A marker is retained In our approximation, we aim to reconstruct the coalescent tree only at a single "focal point" x, although up to a particular node as long as there is at least one lineage leading to this node in which that SNP is not we use the full genotype data from the entire region, as all of this is potentially informative about the tree at separated from the focal point by recombination. We do not model coalescent events in the ARG where only that focal point. Consider two chromosomes that have a very recent common ancestor (at the focal point).
one of the two lines carries the focal point. Therefore, the sequence at internal nodes will always consist of one These chromosomes will normally both inherit a large region of chromosome around the focal point, unintercontiguous fragment of sequence. Our MCMC implementation stores the tree topology, rupted by recombination, from that one common ancestor. Then consider a more distant ancestor that the two node times, and the ancestral sequence at each node. We assume a finite sites mutation model for the markers chromosomes share with a third chromosome in the Indeed, if one wished to perform inference across an infinitely long chromosomal region, the total amount of sequence stored at the ancestral nodes in our representation would be finite, while that in the earlier methods would not.
A more fundamental difference is that, unlike most of the previous model-based approaches to this problem, our genealogical reconstruction is independent of the phenotype data. There are trade-offs in choosing to tackling the problem in this way makes it far easier to combination event occurs, the amount of sequence that reaches the coalescent event is reduced (indicated by the dashes). If assess significance, because we know that under the null this reduction occurs on only one of the two branches, the the phenotypes are randomly distributed among tips of sequence can be restored from the information on the other the tree. It also means that we can calculate posterior branch (as at time t 3 ). But if recombination events occur on densities for multiple disease models using a single both branches, the length of the sequence is reduced (t 2 ).
MCMC run.
Modeling the phenotypes: To compute expressions (6) and (7), we use the following model to evaluate Pr(⌽|x, T x ). that are retained on each branch. (This rather simplistic model is far more computationally convenient than At the unobserved disease locus, let A denote the genotype at the root of the tree T x . We assume that genotype more realistic alternatives.) At some points, sequence is introduced into the genealogy through recombination A mutates to genotype a at rate /2 per unit time, independently on each branch. We further assume that events. We approximate the probability for the introduced sequence by assuming a simple Markov model on alleles in state a do not undergo further mutation. Next, we need to define a model for the genotypethe basis of the allele frequencies in the sample (similar approximations have been used previously by McPeek phenotype relationship for each of the three diploid genotypes at the susceptibility locus: namely, Pr(φ|AA), and Strahs 1999; Morris et al. 2000; Liu et al. 2001; Morris et al. 2002) . The population recombination rate Pr(φ|Aa), and Pr(φ|aa), where φ refers to a particular phenotype value (e.g., affected/unaffected or a quanand the mutation rate are generally unknown in advance and are estimated from the data within the titative measure). For a binary trait, these three probabilities denote simply the genotypic penetrances: e.g., MCMC scheme, assuming uniform rates along the sequence. A more precise specification of the model and Pr(Affected|AA). In practice, the situation is often complicated by the fact that the sampled individuals may not algorithms is provided in appendix a. Overall, our model is similar to those of earlier apbe randomly ascertained. In that case, the estimated "penetrances" really correspond to Pr(φ|AA, S), Pr(φ|Aa, S), proaches such as the haplotype-sharing model of McPeek and Strahs (1999) and the coalescent model of Morris and Pr(φ|aa, S) , where S refers to some sampling scheme (e.g., choosing equal numbers of cases and controls). et al. (2002) . However, we focus on chromosomal sharing backward in time, rather than on decay of sharing In the algorithm presented here, we assume that the affection status of the two chromosomes in an individual from an ancestral haplotype. In part, this reflects our shift away from modeling only affected chromosomes can be treated independently from each other and from the frequency of the disease mutation: i.e., P A (φ) is the to modeling the tree for all chromosomes. The representation used by those earlier studies means that they probability that a chromosome with genotype A comes from an individual with phenotype φ, and analogously for P a (φ). In potentially have to sum over possible ancestral genotypes at sites far away from the focal point x, which are the binary situation, this model has two independent parameters: P A (1) ϭ 1 Ϫ P A (0) and P a (1) ϭ 1 Ϫ P a (0). not ancestral to any of the sampled chromosomes and about which there is therefore no information. Storing
In this case the ratio P A (φ)/P a (φ) corresponds directly to the relative risk of allele A, conditional on the sampling all this extra information is likely to be detrimental in an MCMC scheme, as it presumably impedes rearrangescheme. As another example, for a normally distributed trait, P A (φ) and P a (φ) are the densities of two normal ments of the topology. Thus, we believe that our representation can potentially improve both MCMC mixing distributions at φ and would be characterized by mean and variance parameters. Note that most values of P A (φ) and the computational burden involved in each update.
and P a (φ) do not correspond to a single genetic model Finally, it remains to determine the mutation rate, , at the unobserved disease locus. It seems unlikely that that exists as the mapping from (P A (φ), P a (φ)) to (Pr(φ|AA), Pr(φ|Aa), Pr(φ|aa)) is dependent on the frequency of much information about will be in the data; hence we prefer to set it to a plausible value, a priori. For a the disease mutation. Nevertheless, this factorization of the penetrance parameters is computationally convesimilar model, argued that the most biologically plausible values for this parameter are in the nient and allows for an efficient analysis of T x .
Of course, it is not known in advance which chromorange of ‫,0.1-1.0ف‬ corresponding to low and moderate levels of allelic heterogeneity, respectively. somes are A and which are a, so we compute the likelihood of the phenotype data by summing over the possiMultiple testing: Typically, association-mapping studies consist of large numbers of statistical tests. To acble arrangements of mutations at the disease locus. Under the alternative hypothesis, most arrangements count for this, it is common practice to report a P-value that measures the significance of the largest departure of mutations will be relatively unsupported by the data, while branches leading to clusters of affected chromofrom the null hypothesis anywhere in the data set. The simplest approach is to apply a Bonferroni correction somes will have high support for containing mutations. Let M record which branches of the tree contain disease (i.e., multiplying the P-value by the number of tests), but this tends to be unnecessarily conservative because mutations and ␥ ʚ {1, . . . , n} be the set of chromosomes that carry a disease mutation according to M (i.e., the the association tests at neighboring positions are correlated. descendants of M) and let ␤ be the set of chromosomes that do not carry a mutation, i.e., ␤ ϭ {1, . . . , n}\␥.
A more appealing solution is to use randomization techniques to obtain an empirical overall P-value (cf. Then we calculate McIntyre et al. 2000) . The basic idea is to hold all
. the genotype data constant and randomly permute the phenotype labels. For each permuted set, the tests of (9) association are repeated, and the smallest P-value for that set is recorded. Then the experiment-wide signifiFor a case-control data set this can be written as cance of an observed P-value p i is estimated by the frac-
tion of random data sets whose smallest value is Յp i . The latter procedure is practical only if the test of where n i d and n i h count the number of i-type chromoassociation is computationally fast. For the method prosomes (where i ʦ {A, a}) from affected and healthy posed in this article, the inference of ancestries is indeindividuals, respectively. Equation 9 can be evaluated pendent of phenotypes. Therefore, the trees need to efficiently using a peeling algorithm (Felsenstein 1981) .
be generated only once in this scheme and the sampled The details of this algorithm are provided in appendix trees are stored in computer memory. Then, the likelib. Calculations for general diploid penetrance models hood calculations can be performed on these trees using are much more computationally intensive, and we will both the real and randomized phenotype data to obtain present those elsewhere. the appropriate empirical distribution. For our Bayesian analysis, we take the prior for the For a whole-genome scan, a permutation test with the parameters governing P A (φ) and P a (φ) to be uniform proposed peeling strategy is rather daunting. Perand independent on a bounded set ⌬ and average the forming the peeling analysis for 1000 permutations on likelihoods over this prior. By allowing any possible orone tree of 100 cases and 100 controls takes ‫6ف‬ min der for the penetrances under the alternative model, on a modern desktop machine. Thus, a whole-genome we allow for the possibility that the ancestral allele may permutation test with one focal point every 50 kb, 100 actually be the high-risk allele, as observed at some hutrees per focal point, and a penetrance grid of 19 ϫ 19 man disease loci, including ApoE (Fullerton et al. 2000) .
values would take ‫000,057ف‬ processor hours. For significance testing, we test the null hypothesis that A rather different solution for genome-wide scans P A (φ) ϭ P a (φ) compared to the alternative model where of association may be to apply the false discovery rate the parameters governing P A (φ) and P a (φ) can take on criterion, as this tends to be robust to local correlation any values independently. Standard theory suggests that when there are enough independent data (Benjamini twice the log-likelihood ratio of the alternative model, and Hochberg 1995; Sabatti et al. 2003 doing so, we would properly account for the impact of about the presence of disease variation will come from the degree to which case and control chromosomes haplotype uncertainty on the analysis. In fact, Morris et al. (2004) concluded that doing so increased the accucluster on the tree, so bias in the branch length estimates may not have a serious impact on inferences about the racy of their fine-mapping algorithm (compared to the answers obtained after estimating haplotypes via a rather location of disease variation. The next section provides results supporting this view. simple EM procedure). However, it is already a difficult problem to sample adequately from the posterior distriAnother factor not considered in our current implementation is the possibility of variable recombination bution of trees given known haplotypes and it is unclear to us that the added burden of estimating haplotypes rate (e.g., Jeffreys et al. 2001 ). Since recombination rates appear to vary considerably over quite fine scales, within the MCMC scheme represents a sensible tradeoff. Therefore, we currently use point estimates of the this is probably an important biological feature to include in analysis. One route forward would be for us to estimate haplotypes obtained from PHASE 2.0 Stephens and Donnelly 2003) . We also currently separate recombination parameters in each intermarker interval, within the MCMC scheme (perhaps correlated use PHASE to impute missing genotypes.
False positives due to population structure: It has across neighboring intervals). It is unclear how much this would add to the computational burden of convergence long been known that case-control studies of association are susceptible to high type 1 error rates when the samand mixing. In the short term, it would be possible to use a separate computational method to estimate these rates ples are drawn from structured or admixed populations (Lander and Schork 1994) . Therefore, we advise using prior to analysis with local approximation to the ancestral recombination graph (LATAG; e.g., using Li and unlinked markers to detect problems of population structure (Pritchard and Rosenberg 1999) , prior to
Stephens 2003) and to modify the input file to reflect the estimated genetic distances. using the association-mapping methods presented here.
When population structure is problematic, there are Software: The algorithms presented here have been implemented in a program called LATAG. The program two types of methods that aim to correct for it: genomic control (Devlin and Roeder 1999) and structured assois available on request from S. Zöllner. ciation (Pritchard et al. 2000; Satten et al. 2001) . It seems likely that some form of genomic control correc-TESTING AND APPLICATIONS: SIMULATED DATA tion might apply to our new tests, but it is not clear to us how to obtain this correction theoretically. It should
To provide a systematic assessment of our algorithm we simulated 50 data sets, each representing a finebe possible to obtain robust P-values using the structured association approach roughly as follows. First, one mapping study or a test for association within a candidate region. Each data set consists of 30 diploid cases would apply a clustering method to the unlinked markers to estimate the ancestry of the sampled individuals and 30 diploid controls that have been genotyped for a set of markers across a region of 1 cM. Our model (Pritchard et al. 2000; Satten et al. 2001 ) and the phenotype frequencies across subpopulations. Then, the corresponds to a scenario of a complex disease locus with relatively large penetrance differences (since the phenotype labels could be randomly permuted across individuals while preserving the overall phenotype fresample sizes are small) and with moderate allelic heterogeneity at the disease locus. quencies within subpopulations. As before, the test statistic of interest would be computed for each permuta-
The data sets were generated as follows. We simulated the ARG, assuming a constant population size of 10,000 tion.
SNP ascertainment and heterogeneous recombination diploid individuals and a uniform recombination rate. On the branches of this ARG, mutations occurred as a rates: In the MCMC algorithm described above, and more fully in appendix a, we assume-for convenience-that
Poisson process according to the infinite sites model. The mutation rate was set so that in typical realizations mutation at the markers can be described using a standard finite sites mutation model with mutation paramethere would be 45-65 markers with minor allele frequency Ͼ0.1 across the 1-cM region. The position of the ter . However, in practice, we aim to apply our method to SNPs: markers for which the mutation rate per site disease locus x s was drawn from a uniform distribution across the region. Mutation events at the disease locus is likely to be very low, but that have been specifically ascertained as polymorphic. Hence, our estimate of were simulated on the tree at that location at rate 1 per unit branch length (in coalescent time), with no back should not be viewed as an estimate of the neutral mutation rate; it is more likely to be roughly the inverse of mutations (cf. Pritchard 2001). This process determines whether each chromosome does, or does not, the expected tree length (if there has usually been one mutation per SNP in the history of the sample). Morecarry a disease mutation. We required that the total frequency of mutation-bearing chromosomes be in the over, the fact that SNPs are often ascertained to have intermediate frequency and that we overestimate may range 0.1-0.2, and if it was not, then we simulated a new set of disease mutations at the same location. This lead to some distortion in the estimated branch lengths. However, we anticipate that most of the information procedure generated a total of 10-25 disease mutations across the entire population, although many of the muposterior probability. The running time for each data set was ‫5ف‬ hr on a 2.4-GHz processor with 512 K memory. tations were redundant or at low frequency.
To assign phenotypes, we used the following peneFor comparison, we also analyzed each data set with DHSMAP-map 2.0 using the standard settings suggested trances: a homozygote wild type showed the disease phenotype with probability P hw ϭ 0.05, a heterozygous in the program package. This program generated point estimates for the locus of disease mutation and two genotype showed it with probability P he ϭ 0.1, and a homozygous mutant showed it with probability P hm ϭ 95% confidence intervals: the first assuming a star-like phylogeny among cases, and the second using a correc-0.8. According to these penetrances, we then created 30 case and 30 control individuals by sampling without tion to account for the additional correlation among cases that results from relatedness. replacement from the simulated population of 20,000 chromosomes, as follows. Let n be the remaining numSignificance tests were performed by two methods. First we calculated ber of wild-type chromosomes in the population and m be the remaining number of mutant chromosomes in L m ϭ max {L A (⌽; x i , P alt , G ) : i ʦ {1, . . . , 50}, P alt ʦ ⌬ } the population. Then the next case individual was ho-(10) mozygous for the mutation with probability (P hm · m · (m Ϫ 1)) · (P hm · m · (m Ϫ 1) ϩ 2 · P he · m · n ϩ P hw · and calculated the likelihood ratio according to (1), n · (n Ϫ 1)) Ϫ1 , heterozygous with probability
, and otherwise homozygous for the mutant allele. The diplotypes for each case were then created by sampling the corresponding number of mutant or with L 0 ϭ 0.5
120
. We assigned pointwise significance to wild-type chromosomes. Control individuals were generthis ratio by assuming that 2 ln(LR) is 2 -distributed ated analogously. Across the 50 replicates, we found with 1 d.f. (Other simulations that we have done indicate that 10-33 of the 60 case chromosomes and 0-9 of the that this assumption is somewhat conservative; results control chromosomes carried a disease mutation. not shown.) To estimate global significance, we perAs might be expected for the simulation of a complex muted case and control status among the 60 individuals disease, not all of the simulated data sets carried much 1000 times, recalculated L m for each permutation (using information about the presence of genetic variation inthe original trees obtained from the data), and counted fluencing the phenotype. For instance, in 22 of the the number of permutations that showed a higher L m generated data sets, the highest single-point association than the original data set anywhere in the region. The signal among the generated markers, calculated as Pearpermutation procedure corrects for multiple testing son's 2 , is Ͻ6.5.
across the region and does not rely on the predicted We analyzed each simulated data set by considering distribution of the likelihood ratio. 50 focal points x 1 , . . . , x 50 , spaced equally across the For comparison we assessed the performance of sin-1-cM region. For each point x i we used LATAG to draw gle-point association analysis by calculating the associa-50 trees from the distribution Pr(T x i |G, x i ). To ensure tion of each observed marker in a 2 ϫ 2-contingency convergence of the MCMC, we used a burn-in period table with a 2 -statistic and recorded the 2 of the marker of 2.5 ϫ 10 6 iterations for x 1 . As the tree at location x i with the highest value. We assigned significance to this is a good starting guess for trees of the adjacent tree at test statistic in two ways: first, on the basis of the 2 -distrix iϩ1 we used a burn-in of 0.5 ϫ 10 6 iterations for x 2 , . . . , bution with 1 d.f., and second, by performing 1000 x k . We sampled each set of trees {T
} using permutations of phenotypes among the 60 individuals a thinning interval of 10,000 steps and estimated Pr(⌽, and counting the number of permutations in which the G |x i ) according to (6) and (B2) without assuming any highest observed 2 was higher than that observed in prior information about the location of disease mutathe sample. tions. We found that the mean was somewhat unstable To assess convergence, we then repeated the analysis due to occasional large outliers and therefore substiof each data set an additional four times and compared tuted the median for the average in (6). To evaluate (B2) the estimated posterior distributions to assess the conwe summed over a grid of penetrances ⌬ ϭ {0.05, 0.1, vergence of the MCMC and the variability in estimation. . . . , 0.95} ϫ {0.05, 0.1, . . . , 0.95}, setting the disease We calculated the overlap of two credible intervals C 1 mutation rate to 1.0. We calculated the posterior proband C 2 obtained from multiple MCMC analyses of the ability at each locus x i by evaluating same data set as
In addition, we recorded the point estimate for the location of the disease mutation as the x i with the highest where |I | is the length of interval I.
tively flat across the entire region. Some of the data sets contain very little information about the presence or location of disease mutations, and so small random fluctuations in the estimation can shift the peak from one part of the region to another. To further quantify this observation, we computed the correlation between the average pairwise difference of the point estimates with the average posterior likelihood at the point estimate for each data set. We observed that these were strongly negatively correlated (correlation coefficient ϭ Ϫ0.29). The higher the signal that is present in the data (expressed in posterior probability), the smaller the difference is between the point estimates.
In summary, when the data sets contained a strong signal, the concordance between individual runs was distribution is a natural "best guess" for the location of the disease variation. To assess the accuracy of this estimate, we calculated the distance between this point RESULTS estimate and the real locus of the disease mutation for Assessing convergence: An important issue for each simulated data set. Overall, we observed an average MCMC applications is to check the convergence of the error of 0.19 cM with a standard deviation of 0.23 cM. Markov chain, since poor convergence or poor mixing
To evaluate this result, we compared it to the accuracy can lead to unreliable results. While numerous methods of two other point estimators. As a naive estimator, we exist to diagnose MCMC performance (Gammerman chose the position of the marker that has the highest 1997), the most direct approach is to compare the relevel of association with the phenotype, measured using sults from multiple MCMC runs. If the Markov chain the Pearson 2 statistic. This choice is based on the obperforms well, and the samples drawn from the posterior servation that, on average, LD declines with distance. are sufficiently large, then different runs will produce
As an example of an estimator provided by a multipoint similar results. (Conversely, good performance by this method, we analyzed the prediction generated by criterion does not absolutely guarantee that the Markov DHSMAP. chain is working well, but it is certainly encouraging.)
We found that the average distance between the disTo assess the convergence of the LATAG algorithm, ease locus and the SNP with the highest 2 was 0.25 cM we performed five runs for each of the 50 simulated data (standard deviation 0.26 cM) and the distance to the sets. For our simulated data sets we found that on average, DHSMAP point estimate was 0.27 cM (standard deviapairs of 50% credible intervals overlapped by 75% and tion 0.25 cM). The cumulative distributions of the error pairs of 95% credible intervals overlapped by 96%.
in estimation are displayed in Figure 6 . The estimate As a second method of evaluating the convergence generated by LATAG is most likely to be close to the of the MCMC, we compared the point estimates for the real locus of disease mutation. For instance, in 54% of location of disease mutation between the different runs.
all simulations, the LATAG estimate is within 0.1 cM of The average distance between two point estimates on the the real locus, while the naive estimate is within 0.1 cM same data set is 184 kb. This number includes data sets in 44% of all cases and DHSMAP is in the same range where there is very little information about the locus of in 30% of our simulated data sets. disease mutation. Figure 5 displays the point estimates Coverage of credible intervals: A major advantage of for across independent runs, indicating that for most using model-based methods to estimate disease location data sets all five runs produce a similar estimate. Further is that they can also provide a measure of the uncertainty inspection of the results in Figure 5 indicates that in of an estimate. To assess the accuracy of the estimated most cases where there is substantial variation across uncertainty for LATAG, we generated credible intervals of different sizes, ranging from 10 to 90%, on the basis runs, this is because the posterior distribution is rela- -value in a test for association. gesting that our credible intervals may be slightly conservative.
of the posterior distribution for each data set. Figure 7 based 2 of 8.5. In 88% of the simulations, the 2 -test plots the number of data sets for which the disease mugenerated a more significant single-point P-value. tation is located within each size credible interval and However, because the extent of multiple testing may compares those numbers to the expected values. There be different for the two methods, this is not exactly the is good accordance between the values, although it apright comparison. The LATAG analysis consists of 50 pears that for low and intermediate confidence levels tests, many of which are highly correlated, because the the constructed intervals are somewhat conservative and trees may differ little from one focal point to the next. that the posterior distribution generated by LATAG
The SNP-based test consists of about the same number slightly overestimates the uncertainty. The high uncerof tests (one for each marker), and the correlation betainty about the location of the disease mutation is retween tests depends on the LD between the markers. flected in the average size of the confidence intervals, Therefore, a simple Bonferroni correction is too conserwhich range from 0.06 cM for the 10% C.I. to 0.85 cM vative for both test statistics. To perform tests that take for the 90% C.I. the dependence structure in the data into account, we For comparison, we also looked at the 95% confidence obtained P-values for each of the two test statistics by intervals that are generated by DHSMAP. Those intervals permutation (see Simulation methods). We observed that are considerably shorter than the intervals obtained from correcting for multiple tests has a strong impact on the LATAG, at an average length of 0.37 cM for intervals signal of the single-point analysis. For 24% of the data sets, obtained using the correction for pairwise correlation and the single-point analysis produced a region-wide P-value 0.15 cM without that correction. But for both models the Ͻ0.05, while in 30% of the data sets LATAG produced a confidence intervals were too narrow, with 48 and 18%, P-value Ͻ0.05. Furthermore, the two tests do not always respectively, of intervals containing the true disease locus detect the same data sets: one-third of all the data sets (cf. Morris et al. 2002) . In summary, LATAG seems to that showed a significant single-point score did not have provide credible regions that are fairly well calibrated or a significant signal with LATAG, while 45% of all disease perhaps slightly conservative.
loci that were detected with LATAG were not detected Hypothesis testing: To gauge the power of LATAG in with the single-point analysis (Figure 8) . Hence, although a test for association, we assessed for each data set whether LATAG appears to be more powerful on average, there we could detect the simulated region as a region harbormay be some value in performing SNP-based tests of ing a disease mutation. To do this, we calculated the association as well as that approach may detect some likelihood ratio at each focal point according to Equaloci that would not be detected by LATAG. tion 1 and considered the maximal LR that we observed among all focal points as the evidence for association.
For comparison, we also tested each SNP for association TESTING AND APPLICATIONS: REAL DATA with the phenotype, using a standard Pearson 2 -test. We obtained an average maximum value of twice the logTo further illustrate our method we report analyses of two sets of case-control data. One data set was used to likelihood ratio of 5.8 and an average maximum SNP- -test (y-axis) to detect disease-causing loci Figure 9 .-Repeatability across runs. Average posterior likein a test for association. Each point corresponds to one of the lihoods for 10 independent LATAG analyses of the CF data 50 simulated data sets and plots the most significant P-values set are shown. For the location of the disease locus and the obtained for that data set using each method, corrected for resulting posterior credible region refer to Figure 10 . multiple testing within the region. The dotted lines depict the P ϭ 0.05 cutoffs and the diagonal line plots the regression line through the log-log-transformed data.
calculated P(⌽|T i , x) with the peeling algorithm. As the resulting posterior likelihoods seemed to be heavily dependent on a few outliers, we estimated the likelihood map the gene responsible for cystic fibrosis, a simple recessive disorder (Kerem et al. 1989) , while the other P(x |⌽, G) at each position x by taking the median of the likelihoods P(⌽|T i , x) instead of the average sugdata set is from a positional cloning study of a complex disease, type 2 diabetes (Horikawa et al. 2000) .
gested by theory. As before, we used the posterior mode as our point estimate for location. Missing data were Example application 1: Cystic fibrosis: The cystic fibrosis (CF) data set used by Kerem et al. (1989) to map the imputed using PHASE 2.0 .
Results: To provide a simple check of convergence, CFTR locus has been used to evaluate several previous fine-mapping procedures, thus allowing an easy compar- Figure 9 shows the results from the 10 independent analyses of the CF data set. As can be seen, all 10 runs have ison between LATAG and other multipoint methods. The data set was generated to find the gene responsible modes in the same region and yield the same conclusion about the location of the causative variation. for CF, a fully penetrant recessive disorder with an incidence of 1/2500 in Caucasians. Many different disease- Figure 10 summarizes our results across the 10 runs. The posterior distribution is sharply peaked at 867 kb, causing mutations have been observed at the CFTR locus, but the most common mutation, ⌬F508, is at quite near the true location of ⌬F508 (which is at 885 kb). The 95% credible interval is rather narrow, extending high frequency, accounting for 66% of all mutant chromosomes. from 814 to 920 kb. Even though several markers with little association to the trait are in the vicinity of the The data set consists of 23 RFLPs distributed over 1.8 Mb; these were genotyped in 47 affected individuals. deletion (Figure 10 ), the LATAG estimate is quite accurate. It is useful to compare our results to those obtained In addition, 92 control haplotypes were obtained by sampling the nontransmitted parental chromosomes.
by other multipoint methods (see Table 1 , modified from Morris et al. 2002) . For this data set, most of the High levels of association were observed for almost all markers in the region; the marker with the highest highest single-point 2 values lie to the left of the true location of ⌬F508, and so most of the methods err to single-point association ( 2 ϭ 63) is located at 870 kb from the left-hand end of the region. The ⌬F508 mutathe left, with some of the earliest methods (Terwilliger 1995) actually excluding the true location from tion is at 885 kb and is present in 62 of the 94 case chromosomes.
the confidence interval. Note that the LATAG estimate is closer to the true location, and that the 95% credibility We ran 10 independent runs of the Markov chain, estimating the average posterior likelihood at each of region is narrower than that obtained by any of the previous methods. 50 evenly distributed points across the region. Each run had a burn-in of 2.5 ϫ 10 6 steps for the first focal point To assess the ability of LATAG to detect the CF region by association, we calculated a likelihood ratio accordand 10 6 steps for each following focal point. In each run, we sampled 50 trees at each focal point, with a ing to (1) and obtained 2 ln(LR) ϭ 40. Assuming a 2 -distribution with 1 d.f., this log-likelihood ratio has an thinning interval of 10,000 steps. The runs took 8 hr each on a Pentium III processor. For each tree T i , we associated P-value of 3.7 ϫ 10
Ϫ10
. While this is extremely of 85 SNPs distributed over an area of 876 kb. The markers were genotyped in 108 cases and 112 controls. No individual marker shows high association; the marker with the highest LD ( 2 ϭ 9) is located at 121 kb from the left-hand end of the region. The original study also used some additional information from family-sharing patterns that we do not consider here. On the basis of detailed analysis of those data, Horikawa et al. (2000) proposed that a combination of two haplotypes, each consisting of 3 SNPs within the CAPN10 gene, increases the risk of diabetes by two-to fivefold. The three SNPs that make up the haplotype are located at 121, 124, and 134 kb.
We used the PHASE 2.0 algorithm, with recombina- Figure 10 .-Average posterior likelihoods generated by tion in the model , to impute the LATAG for the CF data set (Kerem et al. 1989) . The dots depict phase information and missing genotypes for both cases the association signals of the individual markers as 2 -statistics and controls. Then we used LATAG to infer the poste-(see scale on the right). We display the likelihoods here berior distribution of the location of the disease mutation cause the posterior density is extremely peaked, with 95% of and a P-value for association, as described above. Perits mass inside the box marked by the dashed lines.
forming eight independent runs of the MCMC, we generated a total of 800 draws from the posterior distribusignificant, it is less significant than that obtained from tion P(T |G, x) for each of 50 positions in the sequence. simple tests of association with individual SNPs (six of Each run had a burn-in of 5 ϫ 10 6 steps for the first which yield 2 -values Ͼ50). This may indicate that our point and 10 6 steps for each following point, a thinning likelihood-ratio test does not fit the 2 -approximation interval of 10,000 steps between draws, and took 36 hr very well, particularly far out in the tail of the distribuon a Pentium III processor. tion, or that our test is slightly less powerful in this exResults: Figure 11 plots the estimated posterior distritreme setting. Due to the extremely high level of signifibution for the location of diabetes-associated variation cance, it is infeasible to generate an accurate P-value in this region. From this distribution we estimate the by permutation.
position of the disease mutation at 131 kb, at the same Example application 2: Calpain-10: Our second applilocation as the SNPs that Horikawa et al. (2000) reported cation comes from a positional cloning study that was as defining the key haplotypes. However, the posterior searching for disease variation underlying type 2 diabedistribution is quite wide, with 50% of its mass between tes. Type 2 diabetes is the most common form of diabe-70 and 245 kb. The full 95% credibility region extends tes and in developed countries it affects 10-20% of inbetween 0 and 660 kb, indicating that we can really exdividuals over the age of 45 (Horikawa et al. 2000) .
clude only the right-hand end of this region. We would This appears to be a highly complex disease, with no need larger samples to obtain more precision. gene of major effect, and with environmental factors To assess whether we would have detected this region playing an important role. A linkage study in Mexican by association, on the basis of this data set, we evaluated Americans localized a susceptibility gene to a region (1) and obtained 2 ln(LR) ϭ 6.0 at the posterior mode, on chromosome 2 containing three genes, RNEPEPL1, corresponding to a single-point P-value of 5.3 ϫ 10 Ϫ4 . CAPN10, and GPR35. A data set that was generated by When we correct for multiple testing using the simulation procedure, the overall significance level drops to Horikawa et al. (2000) for positional cloning consists The ⌬F508 mutation, which is responsible for 66% of all CF cases, is located at position 885. Only estimates that are based on the entire data set are presented.
across multiple blocks are potentially quite informative about the order of recent coalescent events. In our method, rather than forcing the user to predefine regions of limited recombination, the algorithm "adapts" to the data, in the sense that quite large regions of shared haplotypes may help to resolve recent coalescent events, while much smaller regions (e.g., corresponding to haplotype blocks) may be the relevant scale for reconstructing the topology of the more ancient coalescent events. Hence, we gather information both from mutation and from recombination events to reconstruct the ancestral trees. By doing so, we can detect association even when there is allelic heterogeneity, and we can gain information about low-frequency disease muta- It is also natural to compare LATAG to recent finemapping algorithms. One major difference between LATAG and most of the previous coalescent-based algoa mildly significant P ϭ 0.02. In contrast, if we assess rithms is that LATAG aims to reconstruct the ancestry the significance of the highest observed single-point of all the sampled chromosomes, not just of case chro-2 by permuting case and control labels, we obtain a mosomes. By considering the ancestry of all individuals nonsignificant P-value of 0.11.
at once, we can deal with more general phenotype modOverall, our results are consistent with the conclusion els and we can model allelic heterogeneity and incomof Horikawa et al. (2000) , that CAPN10 is the gene that plete penetrance in a natural way, although including was responsible for their diabetes linkage signal in this rethis additional information may increase computation gion. However, our analysis cannot exclude GPR35 as the time. This also represents the first multipoint fine-mapdisease gene. As with the original analysis, our strongest ping method for quantitative traits. Our approach can signal is in the CAPN10 region, but our overall signal also produce penetrance estimates under haploid and is only modestly significant. diploid models (the latter to be presented elsewhere), although these estimates may not be straightforward to interpret when the ascertainment of samples is not random. We have not focused on this here, but our DISCUSSION approach also produces a posterior probability that each We have described a new unified method, LATAG, for chromosome carries a disease mutation. This can be association mapping and fine mapping with multipoint used to guide full resequencing of implicated regions. data. Our approach, based on a local approximation to Including control chromosomes in the tree allows us to the ARG, strikes a compromise between modeling the make better use of the control data than earlier methods population genetic processes that produce the data and that used just controls to estimate the SNP allele frethe need for a model that is computationally tractable quencies, as exemplified by the strong performance of for large data sets.
our method on the CF data and on the simulated data. Our association-mapping method is similar in spirit For any model-based approach such as LATAG, it is to earlier tree-based methods (e.g., Templeton et al. worth considering the various modeling assumptions 1987). However, we take a more probabilistic approach and how these might affect the results. In general, it in the sense that we average over the uncertainty in trees seems that most of the inaccuracies of the model can and consider an explicit mutation model at the unobbe overcome by informative data; at worst they might served disease locus. A more fundamental difference is slightly reduce our power and precision (cf. Morris that our tree inference scheme aims to model recombiet al. 2002) . For instance, the Markov model that we nation explicitly, while the earlier methods make the use for LD outside the inherited region is not strictly most sense in small regions without evidence for recomaccurate and might be expected to produce a slight bination. Moreover, even for estimating the tree within a bias toward keeping too much sequence on the tree. haplotype block, markers outside the block may contain Inaccuracies there may explain the tendency toward additional information about that tree. It is typical for conservativeness in the coverage of our credible interthere to be at least some LD between haplotype blocks vals ( Figure 7) . Similarly, the finite sites model used for SNP mutation, ignoring SNP ascertainment, is clearly (Daly et al. 2001) , and patterns of haplotype sharing inaccurate. However, this model is computationally conputing facilities. Nevertheless, improving the algorithm to deal with larger data sets is a focus of our ongoing venient, and it seems likely that the data should overresearch. whelm deficiencies here; again, that view is supported One question that arises in this context is whether to by the results. Besides, allowing recurrent SNP mutation treat haplotype phase from diploid genotypes as known provides an ad hoc way of allowing for gene conversion, when inferring the trees (here we estimated phase using which might otherwise confound our inference.
Phase 2.0; Stephens et al. 2001) . The alternative-which Another issue is that we ignore the ascertainment of is more statistically sound-is to use the MCMC coalescases and natural selection on the disease variants. cent algorithm to mix over unknown phase along with These processes are expected to distort the shape of tree topology. Morris et al. (2004) implemented such the tree (cases will be more closely related than prea method and reported that it produced more accurate dicted under the coalescent model). But this distortion fine-mapping results than did a method that used haploeffect will be most pronounced when the signal is very types estimated by a simple EM algorithm. However, strong (e.g., for a recent highly penetrant mutation, as given that it is already difficult to achieve good MCMC in the CF data). In that case, the data will usually be performance in large data sets of known haplotypes, it strong enough to overwhelm the rather weak coalescent is unclear to us that also mixing over haplotypes is necesprior. In other words, when the coalescent model is sarily a good strategy. We look forward to further refurthest from the truth, the data are likely to be very search on this issue. informative and should override the misspecifications In summary, our new methods provide a coherent of the prior.
framework for achieving different goals of LD-based At present we also assume that even if there are multimapping. Furthermore, they perform well on real and ple disease mutations in a region all of these occur at simulated data, compared to standard existing methods. essentially the same position. This may well be a poor One of the biggest challenges for the future will be to assumption. For example, mutations in different exons develop our current framework so that it can be applied of a single gene might be many kilobases apart. Neither to the massive data sets that will soon be forthcoming our method nor any other existing method would hanin the human genetics community. dle this well; however, dealing with this issue is surely tree space efficiently and produce robust, repeatable results for large data sets (Wall 2000) . As noted above, we use a local approximation to the ARG to substantially simplify the space that we are mixing through. We also further experimentation will be required to help deter- Lander, 2001 High-resolution haplotype structure in the human genome. Nat. Genet. 29: 229-232. mine the best design. The calpain-10 data set, consisting sor and LATAG can make efficient use of modern com-
The goal of the Markov chain Monte Carlo algorithm is to generate trees from the distribution Pr(T x |X ϭ x, G). As before, G denotes haplotype data across some region, and x is a focal point within that region. We treat the unknown genealogy, node times, and ancestral sequence at each node as missing data and use MCMC to integrate over these missing data. For a more detailed description, we need to introduce some more notation. As an aid to the reader, the notation used in this appendix is summarized in Table A1 .
We assume that recombination events and mutation events on one side of x occur independently of events on the other side of x, so that conditional on the tree topology and branch lengths, the full likelihood can be computed as the product of the left-hand and right-hand likelihoods. Thus, it is sufficient to describe mutations and recombinations on the right side of x with the understanding that the same process occurs on the left side. Let us therefore assume, without loss of generality, that x is immediately to the left of marker 1.
The sample we are looking at consists of n chromosomes that are typed at L loci. The marker map can be described by the following variables. Let d i , i ʦ {1, . . . , L} be the physical distance between the focal point x and marker i and let ␣ i be the number of alleles at marker i. Let /2 be the mutation rate of each marker per unit coalescent time, and let /2 be the recombination rate per unit coalescent time per unit distance. That is, recombination events occur between the focal point x and marker i at rate · d i /2 per unit coalescent time.
The coalescent tree T x is described by the following two variables: Let ⍀ ϭ ( n , . . . , 2 ) denote the times between successive coalescent events (e.g., n is the time during which there are n lineages in the tree). Let denote the labeled topology of the tree. For notational purposes, it is convenient to introduce K j , j ʦ {1, . . . , 2n Ϫ 1} as the ordered set of nodes on the tree, so that {K 1 , . . . , K n } are the external nodes, K nϩ1 is the node of the first coalescent event, and K 2nϪ1 is the most recent common ancestor (MRCA). Furthermore, let B ϭ (b 1 , . . . , b 2nϪ2 ) be the vector of branch lengths, where b j is the branch length between node K j and its parental node.
Let s j i ʦ {1, . . . , ␣ i } be the observed or inferred allele at node K j at marker i, and let s j denote the full haplotype {s ) be the vector of all sequence information in internal and external nodes. In this notation G ϭ {s 1 , . . . , s n }. Let r j ʦ {1, . . . , L ϩ 1} be the marker closest to x that is not inherited to node K j from its ancestor due to recombination, where r j ϭ L ϩ 1 indicates that the entire set of markers is inherited. Let R be the vector of all r j . Using this notation, the goal of our algorithm is to sample from Pr(⍀, |s 1 , . ) be the joint vector of unknown parameters. At each step of the algorithm, we draw a candidate value Ã from a proposal density O(·|A, G). Details about the proposals are given below. The candidate value Ã is accepted to replace A with probability ␣(A, Ã ), where
is the usual Metropolis-Hastings ratio; otherwise the old value A is retained. The probabilities Pr(Ã |G) and Pr(A|G) are calculated according to the details given below. As is standard, the initial steps of the Markov chain are discarded, as they are heavily influenced by the starting condition. Inference is then performed on the subsequent set of topologies, with an appropriate thinning interval.
To evaluate (A1), we need to calculate the probabilities Pr(Ã |G) and Pr(A|G). To this end, we first need to establish some basic models for recombination and mutation. 
Mutation model:
We assume a finite sites mutation model with parent-independent mutation at rate /2 per branch, per unit coalescent time. That is, at each marker, mutations occur as a Poisson process at rate /2, and the new allele following a mutation is drawn uniformly at random from the ␣ i possible alleles. (Hence, at a site with two alleles, /2 is twice the biological mutation rate, which counts only mutations that change the allele.) It should be pointed out that as it is used here represents the mutation rate of a preascertained SNP, not the usual mutation rate of a random base pair. Letting node K l be ancestral to K k , then conditional on the fact that no recombination occurs between x and marker i between K l and K k , the allelic state of marker i has the distribution Pr(s 
where a 1 , a 2 ʦ {1, . . . , ␣ i }. Background haplotype probabilities: For the model of the recombination process it is necessary to provide the probability that a haplotype could arise on the part of the ancestry that is not described by T x . Let q, v ʦ {1, . . . , L ϩ 1} be positions on the marker map and (s i ) qՅiϽv be the sequence between those two positions. Then H((s i ) qՅiϽv ) designates the probability of drawing the haplotype (s i ) qՅiϽv from the population. As in some previous work in this area (e.g., McPeek and Strahs 1999; Morris et al. 2002) , we model the likelihood for sequence that recombines into the tree as a first-order Markov process, estimating the allele frequencies and two-site haplotype frequencies as proportional to the sample frequencies plus 1.
Recombination model: Letting the nodes K k , K q be the descendants of node K j , then z j ʦ {1, . . . , L ϩ 1} is defined as z j ϭ max {r k , r q }. Thus z j is the marker closest to x in node K j that will not be inherited to the present. For i ʦ {1, . . . , n}, by definition z i ϭ L ϩ 1. Then the probabilities of recombination events on the branch from K j , conditional on the state at K j , are ratio (A1). In the following, we describe the different proposals employed. Dependent on the nature of the data set, we perform the different proposals at different rates. For every parameter z let z denote the proposed new parameter. Furthermore, we define t i to be the time between node K i and the present. The different changes we propose are:
Propose new : A new is drawn from a uniform distribution on the interval (0.5 · , 2 · ).
Local update of internal nodes: Starting at the terminal nodes, we propose for each node K i an r i , a time t i , and a sequence s i conditional on the sequence and recombination events at surrounding loci. All nodes are visited in each step of the Markov chain.
Major rearrangements: We randomly select a node K i that can be removed from its location, without causing inconsistencies among its parental nodes ( Figure A1 ). Using the notation illustrated in Figure A1 , K i is a candidate to be moved if
Then we consider all other nodes whose parental nodes are older than K i and weight them according to their sequence similarity with K i . Given those weights, we draw one node K c . Let K k be the parental node of K c . We then draw a time t uniformly from the interval (max{t c , t i }, t k ) and propose a new tree where K i coalesces with K j at node K p at time t, while K j and K q coalesce at node K o (see Figure A1 ). We draw new recombinations r j , r c , r i , and r p and a new sequence s r conditional on the information at surrounding nodes.
Minor rearrangements: We draw an internal node K i of the tree. Let K i and K j coalesce at K p and K p and K q coalesce at K o . Then we propose a tree, where K j and K q coalesce at K p and K i and K p coalesce at K o , while the coalescent times remain unchanged. We also propose a new s p and r p .
Reordering of coalescent events: We select a internal node K i that has the direct descendants K k and K l and the parental node K m . Then we select a second internal node K j that has the direct descendants K o and K p and the parental node K q with t j ʦ (max{t k , t l }, t m ) and t i ʦ (max{t o , t p }, t q ) and propose an exchange of times t i and t j .
APPENDIX B: CALCULATING THE PHENOTYPE LIKELIHOODS
Given a tree T x , we need to compute Pr(⌽|X ϭ x, T x ), the probability of observing the arrangement of phenotypes on the tree. To do this, we assume that all disease mutations occur as a Poisson process with rate /2. Furthermore, we assume that multiple mutations on the same chromosomes have no further effect; thus every chromosome that carries at least one mutation has the same distribution of phenotypes. Under this model we have developed the following approach to calculate Pr(⌽|X ϭ x, T x ).
Peeling algorithm: Recall that P φ m denotes the probability that a chromosome comes from an individual with phenotype φ given that it has mutation (m ϭ 0) or at least one mutation (m ϭ 1). Then Pr(⌽|X ϭ x, T x ) can be calculated exactly, using the peeling algorithm (Felsenstein 1981) .
Let m i be an indicator for the mutation status at node K i , where m i ϭ 1, if node K i carries at least one disease mutation and m i ϭ 0 otherwise. Furthermore, let ⌽ i be the phenotypes of all terminal nodes that descend from node K i . Then it is straightforward to calculate Pr(⌽ i |m i ϭ 1), as further mutations on branches below K i do not affect the phenotype (by assumption). Therefore,
where K j denotes the terminal descendants of K i . In the case of a case control phenotype, where ⌽ i consists of a affecteds and u unaffecteds, Equation B1 can be written as
where u is the number of controls and a is the number of cases among the terminal descendants of K i . On the other hand, Pr(⌽ i |m i ϭ 0) is a little more complicated to calculate. Here we can make use of the assumption that conditional on the mutation status phenotypes at each terminal node occur independently. Then mutations on branches are affecting only phenotypes that descend from this branch. Let K y be an internal node of the tree and K s , K t be the descendants of K y . Furthermore, let i be the probability that there is at least one disease mutation on the branch from node i to its parental node, calculated as i ϭ 1 Ϫ e Ϫb i /2 . Then we can write Pr(⌽ y |m y ϭ 0) ϭ (Pr(⌽ s |m s ϭ 0) · (1 Ϫ s ) ϩ Pr(⌽ s |m s ϭ 1) · s ) · (Pr(⌽ t |m t ϭ 0) · (1 Ϫ t ) ϩ Pr(⌽ t |m t ϭ 1) · t ).
While Pr(⌽ s |m s ϭ 1) and Pr(⌽ t |m t ϭ 1) can be calculated according to (B1), Pr(⌽ s |m s ϭ 0) ϭ P φ 0 , if s is a terminal node. Therefore, we can calculate Pr(⌽ y |m y ϭ 0) for every internal node by starting at the most recent nodes and working iteratively backward in time. As Pr(⌽|X ϭ x, T x ) ϭ Pr(⌽ MRCA |m MRCA ϭ 0), this allows us to calculate the likelihood of the phenotypes given the tree.
Integrating over penetrances: The calculations just described are for fixed values of P φ 0 and P φ 1 . Since these are unknown in advance, our Bayesian computations are based on integrating over the space of possible penetrances. To this end, let us assume, these probabilities are governed by a vector P of variables that live on the bounded set ⌬. In the case of a binary phenotype, this vector P consists of the penetrances of the carriers/noncarriers and ⌬ ϭ [0, 1] ϫ [0, 1], while for a normally distributed quantitative phenotype it is composed of the variances and the means of carriers and noncarriers. Then we want to evaluate Pr(⌽|T x , X ϭ x) ϭ Ύ Pʦ⌬ Pr(⌽|T x , X ϭ x, P)Pr(P)dP.
In practice, we are unable to calculate the integral. We therefore substitute
Pr(⌽|T x , X ϭ x, P i )
with ⌬ ϭ {P 1 , . . . , P k } selected from a suitable grid on ⌬. For the analysis presented here, we used (P 
